John D Lambris
Affiliation: University of Pennsylvania
Papanastasiou M, Koutsogiannaki S, Sarigiannis Y, Geisbrecht B, Ricklin D, Lambris J. Structural Implications for the Formation and Function of the Complement Effector Protein iC3b. J Immunol. 2017;198:3326-3335 pubmed publisher
Reis E, DeAngelis R, Chen H, Resuello R, Ricklin D, Lambris J. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology. 2015;220:476-82 pubmed publisher
Rafail S, Kourtzelis I, Foukas P, Markiewski M, DeAngelis R, Guariento M, et al
. Complement deficiency promotes cutaneous wound healing in mice. J Immunol. 2015;194:1285-91 pubmed publisher
..These findings also suggest a previously underappreciated role for complement in wound healing, and may have therapeutic implications for conditions of delayed wound healing. ..
Sfyroera G, Ricklin D, Reis E, Chen H, Wu E, Kaznessis Y, et al
. Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity. J Immunol. 2015;194:3305-16 pubmed publisher
Reis E, Mastellos D, Yancopoulou D, Risitano A, Ricklin D, Lambris J. Applying complement therapeutics to rare diseases. Clin Immunol. 2015;161:225-40 pubmed publisher
..This review provides an overview of the candidates currently in the pharmaceutical pipeline with potential to treat orphan diseases and discusses the molecular mechanisms triggered by complement involved with the disease pathogenesis. ..
Ricklin D, Lambris J. New milestones ahead in complement-targeted therapy. Semin Immunol. 2016;28:208-22 pubmed publisher
Ricklin D, Reis E, Mastellos D, Gros P, Lambris J. Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense. Immunol Rev. 2016;274:33-58 pubmed publisher
Primikyri A, Papanastasiou M, Sarigiannis Y, Koutsogiannaki S, Reis E, Tuplano J, et al
. Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1041-1042:19-26 pubmed publisher
Mastellos D, Reis E, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris J. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology. 2016;221:1046-57 pubmed publisher
..Translational perspectives and considerations are discussed, particularly with regard to the structure-guided drug optimization and clinical advancement of a new generation of C3-targeted peptidic inhibitors. ..